AstraZeneca’s (AZN) third quarter earnings came in at $1.68 per American Depositary Shares (ADS), well above the Zacks Consensus Estimate of $1.36 and $1.32 reported in the year-ago period. Revenues increased 10% at constant exchange rates (CER) to $8.2 billion compared to the same period last year. The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from generic withdrawal, US sales of its H1N1 vaccine and robust growth in emerging markets. AstraZeneca recorded strong sales across all geographies. Sales in North America, Emerging Markets and Established Markets increased (at CER) by 13%, 15% and 4%, respectively. The company expects double-digit revenue growth in Emerging Markets for the full year. Among the product categories, apart from gastrointestinal and oncology, which recorded sales decline of 1% and 10% respectively, all other segments increased their revenues. AstraZeneca recorded more than 26% of ...

On an early Tuesday afternoon, MannKind Corporation announced that they do not expect to find any marketing partner for their inhaled insulin drug candidate Afresa in 2009. The news from MannKind Corporation quickly brought down their shares 31 percent.

In a filing with Securities and Exchange Commission, MannKind said that they have come to a conclusion that it would be better to complete the partnership deal after the Food and Drug Administration rules on Afresa which will happen in January 2010. The company said that they have made a substantial progress towards an agreement with a potential partner and that both the companies believe that it would be better to make a deal only after FDA provides their response.

In March 2009, MannKind had submitted their NDA for Afresa Inhalation Powder and

...

DrStockPick.com Stock Report!

Tuesday September 15, 2009

**************************************************************

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug candidate that inhibits the sodium glucose transporter 2 (SGLT2). LX4211 is Lexicon’s fourth drug candidate currently being tested in Phase 2 clinical trials.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT),

...

BMY, Bristol-Myers Squibb Co.

AZN, AstraZeneca plc

FNXC, Fonix Corp, FNXC.OB

DrStockPick Watch List!

 

DrStockPick Watch List! for Monday August 3, 2009

 

My Picks for Monday August 3, 2009 are:

**************************************************************

BMY, Bristol-Myers Squibb Co. and AZN, AstraZeneca plc

BMY is a global biopharmaceutical company whose mission is to extend and enhance human life.

AZN is a major international healthcare business engaged in the research, development, manufacturing and marketing of prescription medicines and supplier for healthcare services. AstraZeneca is one of the world’s leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

Bristol-Myers Squibb and AstraZeneca entered into a collaboration

...